AUTHORS
Luca Guarnera, MD, Atsushi Marumo, MD2, Aashray Mandala, BS3, Mark David Orland, MD, PhD4, Serhan Unlu, MD5, Carlos Bravo-Perez, MD6, Arda Durmaz, PhD7, Christopher Haddad, BS8, Charlotte Zurowski9, Zachary Brady, BS10, Karol K Gostomczyk11, Varun K. Venkatesh, N/A12, Kartik Lakhotiya, MS13, Anand Dev Tiwari, PhD14, Felipe de Almeida Sartori15, Enrico Attardi, MD16, Ilaria Tiravanti17, Emiliano Fabiani18, Carmelo Gurnari, MD,PhD19, Stephan Hutter, PhD20, Torsten Haferlach, MD, PhD21, Maria Teresa Voso, MD22, Jaroslaw P. Maciejewski, MD, PhD, FACP23, Valeria Visconte, PhD24
AFFILIATIONS
1 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
2 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
3 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
4 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
5 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
6 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
7 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
8 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
9 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
10 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
11 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
12 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
13 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
14 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
15 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
16 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
17 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
18 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
19 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
20 MLL Munich Leukemia Laboratory, Munich, Germany
21 MLL Munich Leukemia Laboratory, Munich, Germany
22 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
23 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
24 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
About 13 years ago our group reported recurrent somatic mutations in SETBP1 affecting the degron motif (residues 868–871) resulting in increased protein levels, leukemogenesis and adverse prognosis (PMID:23832012). Although SETBP1 has been implicated in PP2A inhibition and chromatin regulation, its precise oncogenic function remains elusive. Despite preclinical rationale, neither PP2A activators nor menin inhibitors have shown convincing activity against SETBP1-mutant myeloid neoplasia (MN), leaving this lesion an unmet therapeutic need.
Herein, we investigated the contexts favoring the emergence of SETBP1-mutant clones by defining a) clinical, genomic, and transcriptomic landscapes of SETBP1 mutant MN, b) differences between degron and peri-degron hits (residues 862-867 and 872-874) and c) diversity in clinical contexts.
For this purpose, we assembled a multicenter cohort of 11,756 MN patients (4848 AML, 4531 MDS, 1156 MDS/MPN, 1045 MPN, 176 CML) from our institutions and publicly available data (PMID:35941135, PMID:33666653, PMID:37253784, PMID:34075412, PMID:30333627). 329 patients harbored SETBP1 mutations (347 variants with 18 patients carrying more than one variant). RNA sequencing analyses were performed on AML and MDS/MDS-MPN. Molecular clustering was assessed according to Kewan et al. in 3588 MDS, MDS/MPN and sAML cases (PMID:37253784).
Canonical degron mutations accounted for 288/347 variants (83%) in 275 patients, including 47 AML (21 sAML), 132 MDS, 76 MDS/MPN (2 atypical CML), 19 MPN and 1 CML. Across disease subtypes, SETBP1 mutant cases displayed distinct co-mutational profiles, consistently enriched for proliferative and adverse-risk lesions (ASXL1, 67%; SRSF2, 39%; CBL, 12%; NRAS, 15%; PTPN11, 9%) together with del(7) (20%). Importantly, SETBP1 mutations predicted inferior outcomes in MDS, MDS/MPN and AML but when adjusted for prognostic scores (ELN2022 for AML, IPSS-M for MDS/MDS-MPN) and age, they held no independent impact. These results were consistent with sequential samples analysis in AML/MDS/MDS-MPN cases showing stable clonal burden over time (median VAF t0= 31% vs t1=29%). Conversely, an adverse impact in myelofibrosis was confirmed in cases harboring high-risk mutations (100% of SETBP1 mutants). In terms of non-canonical variants, molecular cluster analysis of 233 SETBP1 mutant MDS/MDS-MPN patients demonstrated that peri-degron variants (n=9) but not non-degron hits (n=15) exhibited a distribution closely resembling canonical degron mutations. Indeed, the exploration of molecular nosology via clustering analysis revealed that both degron and peri-degron mutations grouped in a clinico-molecular cluster enriched for high-risk MDS/sAML and ASXL1, SRSF2 and RUNX1 mutations.
To investigate the biological consequences of SETBP1 activation, transcriptomic analyses compared SETBP1 unmutated cases overexpressing SETBP1 mRNA levels (>90%ile) vs the ones under expressing SETBP1 (<10%ile). In both AML and MDS/MDS-MPN cohorts, SETBP1 overexpression was associated with consistent enrichment of immune related response including interferon-α and -γ, inflammation, adaptive immunity, T-cell activation and cytolytic activity. Immune activation was also seen in SETBP1 mutant vs wild type (WT) cases in MDS/MDS-MPN. The relevance of these pathways was strengthened by our expression-matched analysis comparing SETBP1 mutant vs WT cases with similar SETBP1 expression levels. Immune activation (TNFα via NF-κB, IL6-JAK-STAT3, cytokine mediated signaling and interferon pathways) remained significantly enriched in mutant samples indicating that immune dysregulation is generally associated with SETBP1 mutations.
In addition to the previously reported enrichment of SETBP1 mutations in aplastic anemia (AA) (PMID:36054881), we have identified the presence of immune-mediated conditions among 90 SETBP1 mutant MDS-MDS/MPN cases including monoclonal gammopathy of undetermined potential (11.1%), lymphoid malignancies (17.8%), autoimmune disorders (12.2%) and hemophagocytic lymphohistiocytosis (3.3%). Further, we noticed 3.3% of cases with AA.
Our findings demonstrate that peri-degron variants phenocopy canonical degron mutations and redefine the prognostic impact of SETBP1 mutations in the context of current molecular risk classifications. Our integrated geno-transcriptomic analyses suggest that inflammatory networks may contribute to the selection and maintenance of SETBP1 mutant clones in different disease contexts.
DISCLOSURES
Luca Guarnera, MD: No relevant conflicts of interest to declare.